Business Description
Rhelion Life Sciences Corp
NAICS : 312310
SIC : 3741
ISIN : CA75671E1097
Share Class Description:
STU:4YX0: Ordinary SharesCompare
Compare
Traded in other countries / regions
TRIP.CanadaTRUFF.USA4YX.Germany IPO Date
2020-12-17Description
Red Light Holland Corp is an Ontario-based organization engaged in the legal psychedelic sector, with activities focused on research and development initiatives, consensual data collection, the advancement of naturally derived psychedelic drug development, and the understanding of psilocybin use and consumer experiences. It operates commercial businesses across Europe and North America, including psilocybin truffle sales in the Netherlands legal market and mushroom home grow kits through business-to-business and direct-to-consumer channels. Revenue is comprised of sales of wholesale products consisting of truffles, cannabis seeds and other cannabis products, mushroom home grow kits, functional mushrooms, and functional mushroom gummies. It generates maximum revenue from the Netherlands.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.38 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.21 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -1.99 | |||||
Beneish M-Score | -2.53 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -3.1 | |||||
3-Year EBITDA Growth Rate | -4.6 | |||||
3-Year FCF Growth Rate | 19.1 | |||||
3-Year Book Growth Rate | -25.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 17.24 | |||||
9-Day RSI | 26.68 | |||||
14-Day RSI | 32 | |||||
3-1 Month Momentum % | -17.65 | |||||
6-1 Month Momentum % | 55.56 | |||||
12-1 Month Momentum % | 18.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.98 | |||||
Quick Ratio | 3.71 | |||||
Cash Ratio | 2.9 | |||||
Days Inventory | 135.46 | |||||
Days Sales Outstanding | 46.01 | |||||
Days Payable | 108.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.1 | |||||
Shareholder Yield % | 2.38 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 37.93 | |||||
Operating Margin % | -98.33 | |||||
Net Margin % | -145.46 | |||||
EBITDA Margin % | -161 | |||||
FCF Margin % | -86.97 | |||||
OCF Margin % | -57.51 | |||||
ROE % | -39.93 | |||||
ROA % | -32.75 | |||||
ROIC % | -61.57 | |||||
3-Year ROIIC % | -13.12 | |||||
ROC (Joel Greenblatt) % | -128.8 | |||||
ROCE % | -45.64 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | 10 | |||||
PEG Ratio | 2.86 | |||||
PS Ratio | 3 | |||||
PB Ratio | 1.07 | |||||
Price-to-Tangible-Book | 0.7 | |||||
EV-to-EBIT | -1.33 | |||||
EV-to-EBITDA | -1.41 | |||||
EV-to-Revenue | 2.26 | |||||
EV-to-FCF | -2.6 | |||||
Price-to-GF-Value | 0.7 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.7 | |||||
Price-to-Graham-Number | 0.7 | |||||
Earnings Yield (Greenblatt) % | -75.19 | |||||
FCF Yield % | -20.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rhelion Life Sciences Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2.624 | ||
| EPS (TTM) (€) | -0.003 | ||
| Beta | -2.4873 | ||
| 3-Year Sharpe Ratio | 0.56 | ||
| 3-Year Sortino Ratio | 1.69 | ||
| Volatility % | 355.17 | ||
| 14-Day RSI | 32 | ||
| 14-Day ATR (€) | 0.002445 | ||
| 20-Day SMA (€) | 0.01205 | ||
| 12-1 Month Momentum % | 18.64 | ||
| 52-Week Range (€) | 0.0002 - 0.0266 | ||
| Shares Outstanding (Mil) | 595.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rhelion Life Sciences Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rhelion Life Sciences Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Rhelion Life Sciences Corp Frequently Asked Questions
What is Rhelion Life Sciences Corp(STU:4YX0)'s stock price today?
The current price of STU:4YX0 is €0.01. The 52 week high of STU:4YX0 is €0.03 and 52 week low is €0.00.
When is next earnings date of Rhelion Life Sciences Corp(STU:4YX0)?
The next earnings date of Rhelion Life Sciences Corp(STU:4YX0) is .
Does Rhelion Life Sciences Corp(STU:4YX0) pay dividends? If so, how much?
Rhelion Life Sciences Corp(STU:4YX0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Rhelion Life Sciences Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers